Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | EVP & Chief Commercial Officer | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,770 |
Ending reported balance
After 2026-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-03 · Sale · Disposed 46,417 · Balance 75,329 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Row 2 · 2026-03-03 · Sale · Disposed 3,559 · Balance 71,770 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.
F2: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,559 | $40.99 | $145,879.50 |
DisclosureSEC source: 0001746251-26-000004 · form4-03052026_090346.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,770 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.84 to $41.35, inclusive. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:29 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 46,417 | $40.36 | $1,873,557.22 |
DisclosureSEC source: 0001746251-26-000004 · form4-03052026_090346.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,329 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.835 to $40.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 21,615 | $46.75 | $1,010,501.25 |
DisclosureSEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,746 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 9,977 | $46.75 | $466,424.75 |
DisclosureSEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,361 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 30,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,338 F2 · shares: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,702 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 19,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001746251-26-000002 · form4-02122026_040201.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,636 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 17,600 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001746251-25-000004 · form4-12102025_091236.xml · derivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,600 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,475 | $48.66 | $315,084.51 |
DisclosureSEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,613 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.215 to $49.08, inclusive. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 11,125 | $47.89 | $532,770.69 |
DisclosureSEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,088 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.212 to $48.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 17,600 | $15.90 | $279,840.00 |
DisclosureSEC source: 0001746251-25-000004 · form4-12102025_091236.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:57 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 16,389 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-25-014766 · form4.xml · derivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,389 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:57 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 16,389 | $38.21 | $626,171.25 |
DisclosureSEC source: 0001062993-25-014766 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,613 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:57 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 16,389 | $21.34 | $349,741.26 |
DisclosureSEC source: 0001062993-25-014766 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 4,861 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001062993-25-014526 · form4.xml · derivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,389 Underlying: Common Stock · 4,861 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,861 | $38.03 | $184,880.84 |
DisclosureSEC source: 0001062993-25-014526 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,613 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.00 to $38.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 4,861 | $21.34 | $103,733.74 |
DisclosureSEC source: 0001062993-25-014526 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 21:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 18,881 | $30.03 | $566,983.21 |
DisclosureSEC source: 0001062993-25-006148 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,613 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.48, inclusive. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 1,927 | $30.00 | $57,810.96 |
DisclosureSEC source: 0001062993-25-006148 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,494 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:34 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,255 | $30.00 | $67,661.05 |
DisclosureSEC source: 0001062993-25-005752 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,421 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| March 11, 2025 Filed Mar 18, 2025 23:18 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 15,387 | $30.00 | $461,671.55 |
DisclosureSEC source: 0001062993-25-005834 · form4a.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,676 F1 · date: The original Form 4 filed on March 13, 2025 on behalf of the Reporting Person inadvertently reported the incorrect transaction date. As reported in this amendment, the correct transaction date is March 11, 2025. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:01 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 2,348 | $30.00 | $70,445.87 |
DisclosureSEC source: 0001062993-25-005020 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,063 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.01, inclusive. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:01 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 3,295 | $30.00 | $98,853.62 |
DisclosureSEC source: 0001062993-25-005020 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,411 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 06, 2025 Filed Mar 13, 2025 20:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 15,387 | $30.00 | $461,671.55 |
DisclosureSEC source: 0001062993-25-005396 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,676 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 28, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 21,670 | $30.52 | $661,368.40 |
DisclosureSEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,706 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 7,953 | $30.52 | $242,725.56 |
DisclosureSEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,376 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 26,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,329 F2 · shares: Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 26,411 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 45,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-002179 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,918 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 23,791 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · derivative · entry 6 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,791 shares Expires 2028-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 56,807 | $33.98 | $1,930,455.24 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,902 F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.68 to $34.25, inclusive. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 23,791 | $24.03 | $571,697.73 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 51,209 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · derivative · entry 5 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,791 Underlying: Common Stock · 51,209 shares Expires 2028-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 51,209 | $33.82 | $1,732,093.22 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,918 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.36 to $34.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 51,209 | $24.03 | $1,230,552.27 |
DisclosureSEC source: 0001062993-24-011338 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 664 | $37.15 | $24,669.59 |
DisclosureSEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,918 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.01 to $37.50, inclusive. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 9,336 | $36.38 | $339,600.73 |
DisclosureSEC source: 0001062993-24-004754 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,582 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.96 to $36.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 10,145 | $33.70 | $341,886.50 |
DisclosureSEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,918 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 19,545 | $33.70 | $658,666.50 |
DisclosureSEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,063 F3 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 32,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,608 F2 · shares: Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,286 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003169 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,322 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:19 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 23,560 | $32.28 | $760,519.16 |
DisclosureSEC source: 0001062993-24-001028 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,322 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.01 to $32.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:08 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 13,324 | $26.70 | $355,750.80 |
DisclosureSEC source: 0001062993-23-005854 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,882 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.22 to $27.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 6,797 | $26.75 | $181,819.75 |
DisclosureSEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 4 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,206 F4 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 14,529 | $26.75 | $388,650.75 |
DisclosureSEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,003 F3 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 22,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,532 F2 · price: Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 22,459 performance share units granted in the issuer's three prior fiscal years. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 44,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-003474 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,073 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 69 | $28.58 | $1,972.02 |
DisclosureSEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 3 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,798 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 7,341 | $27.83 | $204,300.03 |
DisclosureSEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 2 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,867 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.49 to $28.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3). Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 10,424 | $27.08 | $282,281.92 |
DisclosureSEC source: 0001062993-23-000826 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.49 to $27.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2). Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 20:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 594 | $17.48 | $10,383.12 |
DisclosureSEC source: 0001062993-22-016312 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,632 F1 · shares: Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 18, 2022 Filed Feb 28, 2022 21:24 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 10,559 | $21.61 | $228,179.99 |
DisclosureSEC source: 0001062993-22-005911 · form4.xml · nonDerivative · entry 1 Dreyer Scott · CIK 0001746251 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,226 F1 · date: This Form 4 is being filed late due to an administrative error. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2021 and amended on September 1, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.22 to $21.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.